Clinical trials begin for drug that may prevent Alzheimer’s disease

Clinical trials are now testing a drug called remternetug, developed by Eli Lilly, which may prevent Alzheimer’s disease before symptoms appear. Researchers from Washington University are focusing on young adults with genetic risks for the disease. Remternetug targets amyloid beta, a protein linked to Alzheimer’s. Unlike existing treatments that start after diagnosis, this drug aims to stop plaque formation up to 20 years before symptoms develop. The trial will include 240 participants with genetic mutations related to early-onset Alzheimer’s. They will receive either remternetug or a placebo over two years, with results expected by 2034.